Pancreatic and prostate cancers remain some of the deadliest and most treatment-limited cancers today. Pancreatic cancer will claim over 52,000 lives this year. Prostate cancer is the second leading cause of cancer death in American men, with few options beyond hormone therapy. Oncology CoPilot uses AI to match patients’ gene expression profiles to FDA-approved therapies, helping oncologists identify effective treatments—even when standard options fall short. Designed for tumor boards and clinicians tackling complex cases, Oncology CoPilot delivers personalized insights and supports real-world evidence generation to accelerate adoption. Together, we can offer smarter, more targeted cancer care—now.

Oncology CoPilot is revolutionizing cancer care by bridging the gap between cutting-edge innovation and real-world treatments, offering patients the best fighting chance. Its advanced AI platform analyzes individual gene expression profiles to pinpoint effective precise therapies available today. By democratizing access, it ensures that patients nationwide can receive the same level of advanced care typically reserved for top cancer institutions. Additionally, the platform reduces costs by minimizing trial-and-error treatments and improving patient outcomes. It also expedites clinical trial recruitment, ultimately accelerating FDA approvals for new therapies.

Cancer treatment is an ongoing battle, with tumors constantly evolving and biomarker therapies benefiting only 8% of patients. Big Pharma’s approach—dividing patients into smaller groups fails to offer a scalable solution. Oncology CoPilot changes the game, using gene expression and AI to match patients with existing FDA-approved therapies, delivering effective treatment now. No more chasing mutations—this powerful tool is designed for tumor boards and oncologists to navigate complex cases and provide truly personalized care.

Precision AI Solutions has developed a comprehensive ecosystem that integrates state-of-the-art NSG technologies with advanced AI algorithms to streamline the analysis of complex tumor gene expression data. Their platform generates personalized, ranked treatment options, empowering clinicians to make patient-specific treatment decisions in less time and with a higher degree of efficacy. The automation of gene expression data analysis reduces the time and resources required to make treatment decisions, generating cost savings for healthcare providers while simultaneously improving patient outcomes. The Company has filed provisional IP, launched their initial product, and formed key partnerships with top tier cancer research institutions, including the US National Cancer Institute. Clinical trials, oncologist feedback collection, and further product development are underway. We seeking funding to initiate captive NGS lab operations, support a full product launch, execute a broader marketing strategy, and scale operations. The Company is also receptive to promising M&A opportunities with complementary potential partners.

Today, cancer patients face a paradox: over 240 treatment options exist, yet success rates remain low—even with identified biomarkers. Oncology CoPilot is an AI-driven platform designed to improve outcomes across healthcare stakeholders. By analyzing gene expression profiling data, this approach reveals the intricate biology of each patient’s tumor, providing personalized therapy recommendations ranked by their likelihood of response. This enables oncologists to make informed, precise treatment decisions, ensuring patients receive the most effective, and tailored therapies.